hotspot -WSS

hotspot

author：entertainment 2025-09-27 21:54:43 - browse：3971

Illustration of a red heart. -- health coverage from STAT — Adobe

Novo Nordisk’s obesity drug Wegovy cut the risk of major heart complications by 20% in a closely watched trial, results that could streamline insurance coverage and spur even greater demand for the highly popular therapy.

The milestone Select trial of about 17,500 patients is the first to show that an obesity medication leads to long-term cardiovascular benefits. The company reported only the topline figure in a press release Tuesday, and did not break out the reductions it said were seen in heart attacks, strokes, and cardiovascular deaths — the combined components of the study’s primary outcome. It said all three contributed to the decrease in cardiovascular events in the group that received Wegovy compared with participants given a placebo.

The 20% reduction was greater than many observers were expecting. In a research note Tuesday, Jefferies analysts called the results a “best case” outcome. “If they play baseball in Denmark,” Barclays analyst Emily Field wrote in a note, “Wegovy just hit a home run.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Why the drug industry's warnings on the IRA's impact fall short

focus

explore

WSS

How the messy conversation about Dolly changed bioethics

STAT Readout: Friday, Oct. 20 biotech updates

The struggle to figure out which patients 'deserve' Wegovy

Readout LOUD podcast: Live from the 2023 STAT Summit

UnitedHealth, Optum discontinue NaviHealth name

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

explore

hotspot

hotspot

New air purifier tech could be key to improving indoor air quality

What happened to the House vote on health price transparency?

In Memoriam: Notable people who died in 2023

STAT Readout: Friday, Oct. 20 biotech updates

Trump demands the U.S. pay no more for drugs than other countries … again

Patients, doctors press FTC to beef up hospital merger scrutiny

As demand for Covid shots wanes, Moderna seeks its next success

Roche acquires Telavant from Roivant, adding experimental IBD treatment

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Cassava Sciences’ Alzheimer’s clinical trials should be halted

knowledge

FDA clears Verve to begin U.S. study of gene

FDA weighs limits of animal data in assessing artificial wombs

Patients, doctors press FTC to beef up hospital merger scrutiny

David Liu startup to focus on CRISPR delivery

David Liu startup to focus on CRISPR delivery

Roivant's CEO is a star, but biotech's black hole persists

leisure time

focus

explore

explore